<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>PILMAN &#187; tightening</title>
	<atom:link href="http://www.tapanray.in/tag/tightening/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.tapanray.in</link>
	<description>A Tapan Ray Website</description>
	<lastBuildDate>Sun, 22 Mar 2026 10:59:18 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.4.2</generator>
		<item>
		<title>After Mollycoddling China Cracks Down on Pharma MNCs&#8230;But Why Now?</title>
		<link>http://www.tapanray.in/after-mollycoddling-china-cracks-down-on-pharma-mncs-but-why-now/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=after-mollycoddling-china-cracks-down-on-pharma-mncs-but-why-now</link>
		<comments>http://www.tapanray.in/after-mollycoddling-china-cracks-down-on-pharma-mncs-but-why-now/#comments</comments>
		<pubDate>Mon, 22 Jul 2013 00:00:45 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[abbott]]></category>
		<category><![CDATA[aeon]]></category>
		<category><![CDATA[affordable]]></category>
		<category><![CDATA[Anathema]]></category>
		<category><![CDATA[AstraZeneca]]></category>
		<category><![CDATA[Baxter]]></category>
		<category><![CDATA[Bayer]]></category>
		<category><![CDATA[Chen]]></category>
		<category><![CDATA[China]]></category>
		<category><![CDATA[Chinese]]></category>
		<category><![CDATA[clampdown]]></category>
		<category><![CDATA[contaminated]]></category>
		<category><![CDATA[core]]></category>
		<category><![CDATA[crackdown]]></category>
		<category><![CDATA[Danone]]></category>
		<category><![CDATA[distribution]]></category>
		<category><![CDATA[Dragon]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[EliLilly]]></category>
		<category><![CDATA[enforced]]></category>
		<category><![CDATA[exemplary]]></category>
		<category><![CDATA[GlaxoSmithKline]]></category>
		<category><![CDATA[global]]></category>
		<category><![CDATA[Government]]></category>
		<category><![CDATA[grip]]></category>
		<category><![CDATA[growth]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[harsh]]></category>
		<category><![CDATA[hazards]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[is]]></category>
		<category><![CDATA[its]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[land]]></category>
		<category><![CDATA[Major]]></category>
		<category><![CDATA[manufacturing]]></category>
		<category><![CDATA[meat]]></category>
		<category><![CDATA[Medicines]]></category>
		<category><![CDATA[Merck]]></category>
		<category><![CDATA[milk]]></category>
		<category><![CDATA[mollycoddling]]></category>
		<category><![CDATA[monopolistic]]></category>
		<category><![CDATA[Nestle]]></category>
		<category><![CDATA[Novartis]]></category>
		<category><![CDATA[NovoNordisk]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[population]]></category>
		<category><![CDATA[powder]]></category>
		<category><![CDATA[price]]></category>
		<category><![CDATA[Pricing]]></category>
		<category><![CDATA[principle]]></category>
		<category><![CDATA[R&D]]></category>
		<category><![CDATA[rat]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Reform]]></category>
		<category><![CDATA[Regulatory]]></category>
		<category><![CDATA[Safety]]></category>
		<category><![CDATA[sales]]></category>
		<category><![CDATA[Sanofi]]></category>
		<category><![CDATA[staggering]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[tightening]]></category>
		<category><![CDATA[violations]]></category>
		<category><![CDATA[Zu]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=2948</guid>
		<description><![CDATA[In tandem with exemplary growth in the healthcare sector, China has started confronting with some consequential hazards in form of serious regulatory violations involving, besides many others, hospitals, pharmaceutical pricing and food and drug safety, which reportedly include contaminated milk powder and &#8230; <a href="http://www.tapanray.in/after-mollycoddling-china-cracks-down-on-pharma-mncs-but-why-now/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/after-mollycoddling-china-cracks-down-on-pharma-mncs-but-why-now/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>The ruckus over Clinical Trials in India compels Government tightening regulations before flooring gas pedal for regional leadership</title>
		<link>http://www.tapanray.in/the-ruckus-over-clinical-trials-in-india-compels-government-tightening-regulations-before-flooring-gas-pedal-for-regional-leadership/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=the-ruckus-over-clinical-trials-in-india-compels-government-tightening-regulations-before-flooring-gas-pedal-for-regional-leadership</link>
		<comments>http://www.tapanray.in/the-ruckus-over-clinical-trials-in-india-compels-government-tightening-regulations-before-flooring-gas-pedal-for-regional-leadership/#comments</comments>
		<pubDate>Mon, 13 Aug 2012 00:00:40 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[abbott]]></category>
		<category><![CDATA[before]]></category>
		<category><![CDATA[Biotech]]></category>
		<category><![CDATA[Clinical]]></category>
		<category><![CDATA[compels]]></category>
		<category><![CDATA[Compulsory Licensing]]></category>
		<category><![CDATA[Counterfeit]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[Ethical Marketing]]></category>
		<category><![CDATA[FDI]]></category>
		<category><![CDATA[flooring]]></category>
		<category><![CDATA[for]]></category>
		<category><![CDATA[gas]]></category>
		<category><![CDATA[glaxo]]></category>
		<category><![CDATA[Government]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Hospital]]></category>
		<category><![CDATA[in]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[innovation]]></category>
		<category><![CDATA[IPR]]></category>
		<category><![CDATA[kopran]]></category>
		<category><![CDATA[leadership]]></category>
		<category><![CDATA[Legal]]></category>
		<category><![CDATA[Medical Diagnostics]]></category>
		<category><![CDATA[medicine]]></category>
		<category><![CDATA[Neutraceutical]]></category>
		<category><![CDATA[NPPA]]></category>
		<category><![CDATA[OPPI]]></category>
		<category><![CDATA[over]]></category>
		<category><![CDATA[Patents]]></category>
		<category><![CDATA[Patient]]></category>
		<category><![CDATA[pedal]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[PHC]]></category>
		<category><![CDATA[Policy]]></category>
		<category><![CDATA[Pricing]]></category>
		<category><![CDATA[RDP]]></category>
		<category><![CDATA[regional]]></category>
		<category><![CDATA[regulations]]></category>
		<category><![CDATA[Regulatory]]></category>
		<category><![CDATA[Research & Development]]></category>
		<category><![CDATA[ruckus]]></category>
		<category><![CDATA[sami]]></category>
		<category><![CDATA[Spurious]]></category>
		<category><![CDATA[stakeholders]]></category>
		<category><![CDATA[strategy]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[therapeutic]]></category>
		<category><![CDATA[tightening]]></category>
		<category><![CDATA[Trials]]></category>

		<guid isPermaLink="false">http://tapanray.in/index.php/?p=52</guid>
		<description><![CDATA[The subject of Clinical Trials in India has created a huge ruckus, mainly for wide spread alleged malpractices, abuse and misuse of the fragile regulations of the country by the players in this field. The issue is not just of &#8230; <a href="http://www.tapanray.in/the-ruckus-over-clinical-trials-in-india-compels-government-tightening-regulations-before-flooring-gas-pedal-for-regional-leadership/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/the-ruckus-over-clinical-trials-in-india-compels-government-tightening-regulations-before-flooring-gas-pedal-for-regional-leadership/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
